Selective Targeting of NRF2-High Pancreatic Ductal Adenocarcinoma with an NQO1-Activatable Prodrug

Scientists showed that NRF2^high PDAC can be selectively controlled by a prodrug, C29h, that is specifically activated by the NRF2-inducible enzyme NAD(P)H:quinone oxidoreductase-1 (NQO1).